ABSTRACT
Due to the high incidence and aggressiveness of breast cancer, the understanding of specific factors associated with the profile of the disease is necessary. In this context, the aim of the study was to analyze data from 155 patients with breast cancer, attended at a reference hospital for Oncology of the Unified Health System (SUS), in the period 2015-2020, in the southwest region of Paraná, Brazil. Using multivariate statistical analysis, sample data were divided into three clusters. The heterogeneity between clusters was obtained by Ward’s method. The clinical and pathological variables obtained from the patients’ medical records were: presence of intratumoral emboli, presence of lymph nodes, menopausal status, molecular subtype of breast cancer, histological grade, TNM staging of the disease, tumor size (cm), age at diagnosis (years), weight (kg), height (m2) and body mass index (BMI) (kg/m2). From the data of the total sample, it is observed that 70% of the patients were in menopause at diagnosis, 31.5% had tumors containing emboli, and 41% had positive lymph nodes. The prevalence of Luminal subtype B tumors, intermediate histological grade, and TNM staging II was verified. Furthermore, the prevalence of the disease was higher in women aged over 50 years, representing 66% of cases. The BMI of the patients ranged from 17.63 kg/m2 to 51.26 kg/m2, with 26.45% of the patients with a BMI below 25 kg/m2, 40.65% with a BMI between 25 kg/m2 and 30 kg/m2 and 32.9% with BMI above 30 kg/m2. Cluster analysis, using the spatial distribution of patients, showed that the region of Vale do Iguaçu was the region with the worst averages for clinical-pathological variables, while the region of Vale do Marrecas had the highest number of breast cancer cases.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CAAE 35524814.4.0000.0107
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Board of Western Parana State University, through Plataforma Brasil, under the number CAAE 35524814.4.0000.0107, where CAAE stands for Certificate of Presentation of Ethical Appreciation. The study included 155 patients with a confirmed diagnosis of breast cancer through biopsy.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sequential data used contain information from biopsy samples taken serially from women who had lesions suggestive of breast cancer, visualized by imaging tests (mammography, ultrasound, or MRI) and physical examinations, in the period from May 2015 to March 2020. Data confidentiality was maintained in accordance with clinical research guidelines.
